Table 1 Basic information of included studies

Keith C2019

Empagliflozin/placebo

10–25 mg

HcA1c, 24H-SBP/DBP, office SBP/DBP

Basic antihypertensive and hypoglycemic program

12/24 week

Kazuomi 2019

Empagliflozin/placebo

10 mg

24H SBP/DBP, HbA1, body weight

Basic hypoglycemic and antihypertensive drugs, including ARB

12 week

Michael 2015

Dapagliflozin/placebo

10 mg

24HSBP, office SBP, HbA1c, body weight

Basic hypoglycemic and antihypertensive drugs, including ARB/ACEI

12 week

Tikkanen 2015

Empagliflozin/placebo

10/25 mg

24H SBP/DBP, office SBP/DBP, 55.1/54.8HbA1, body weight

Basic antihypertensive and hypoglycemic program

12 week

Heerspink 2016

Dapagliflozin/placebo

10 mg

Office SBP/DBP, HbA1, body weight

Basic hypoglycemic and antihypertensive drugs, including ARB/ACEI

12 week

Ferreira 2020

Empagliflozin/placebo

10/25 mg

Office SBP, HbA1, body weight

Basic hypoglycemic and antihypertensive drugs, including diuretics

14 week

LanCheng 2021

Empagliflozin/placebo

25 mg

24HSBP/DBP, office SBP/DBP

Basic hypoglycemic and antihypertensive drugs

12 week

Amin 2011

Empagliflozin/placebo

25 mg

24HSBP/DBP

Stop the basic hypoglycemic and antihypertensive regimen 3 weeks before randomization

4 week

Raymond 2015

Canagliflozin/placebo

100/300 mg

24HSBP/DBP

Basic hypoglycemic and antihypertensive drugs, including ARB/ACEI

6 week

Weber 2015

Dapagliflozin/placebo

10 mg

Office SBP/DBP, HbA1c, 24H SBP

Basic hypoglycemic and antihypertensive drugs, including ARB/ACEI

12 week